Protagenic Therapeutics, Inc.
PTIX
$0.92
-$0.11-10.32%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 165.61% | 138.09% | -- | -- | -- |
| Total Depreciation and Amortization | 257.14% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 57.24% | 161.82% | -- | -- | -- |
| Total Other Non-Cash Items | -388.76% | -958.36% | -- | -- | -- |
| Change in Net Operating Assets | -12.31% | 229.97% | -- | -- | -- |
| Cash from Operations | 21.07% | -91.69% | -- | -- | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -132.87% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -133.22% | -- | -- | -- | -- |
| Total Debt Issued | -101.23% | -64.28% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 2,172,500.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -109.38% | 146.38% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 40.38% | -637.23% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -204.36% | 11,397.69% | -- | -- | -- |